Webcast Link: QRxPharma Presentation at Noble Financial's Equity Conference
11AM EDT, 7 June 2010
1 June 2010

ASX Spotlight: John Holaday, Managing Director and CEO, QRxPharma
24 May 2010

QRxPharma Successfully Completes Comparative Phase 1 Proof-of- Concept Study for MoxDuo®CR Tablet Formulation
10 May 2010

QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo®IR in Patients with Post-Surgical Pain
4 May 2010

QRxPharma Successfully Completes Pivotal Phase 3 Combination Rule Study for MoxDuo®IR in Patients with Post-Surgical Pain
14 April 2010

QRxPharma Files IND for MoxDuo®CR; Initiates Phase 1 Trial of Controlled-Release Dual-Opioid™ Formulation for Use in Chronic Pain
30 March 2010

QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo®IV 
23 February 2010

QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo™ IR Dual-Opioid™ for NDA Submission 
10 February 2010

BioTech Nation Podcast with Dr. Moira Gunn [mp3 Audio]
19 January 2010

QRxPharma Initiates Pivotal Phase 3 Study of MoxDuo™IR For Moderate to Severe Acute Pain 
30 November 2009

QRxPharma Limited Announces A $21.6 Million Fully Underwritten Capital Raising 
16 November 2009

QRxPharma Announces Completion of Strategic Alliance Deal with Liaoning Nuokang Medicines Co Ltd for the Development of Venomics Assets
20 October 2009

QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo™CR  
12 October 2009

MoxDuo™ IR Demonstrates Fewer Side Effects than Percocet®  
26 August 2009

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo™ IV Pain Therapy  
23 July 2009

QRxPharma Successfully Completes Comparative Study for Dual-Opioid™ Pain Therapy 
20 April 2009

RedChip Announces CEO Interviews and Company Presentations from Its 2009 San Francisco Conference Now Available Online
8 April 2009

QRxPharma Initiates Second Comparative Study for MoxDuo™ IR Dual-Opioid™ Pain Therapy
19 February 2009

QRxPharma Initiates Comparative Study for MoxDuoIR™ Dual-Opioid™ Pain Therapy
16 December 2008

QRxPharma and University of Alabama at Birmingham Collaborate on Research Program for Parkinson’s Disease 
29 October 2008

FDA Accepts Streamlined Phase 3 Development Plan for Q8003IR “Dual Opioid” Pain Therapy 
5 August 2008

QRxPharma Begins Trading on the International OTCQX 
1 July 2008

QRxPharma Releases Additional Phase 3 Data for Q8003IR ‘Dual Opioid’ Pain Therapy 
22 May 2008

QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 
5 May 2008

Bioshares: The Commercial Context for QRxPharma’s QR8003 
11 April 2008

The Commercial Context for QRxPharma’s QR8003QRxPharma Limited Interim Report for the half-year ended 31 December 2007 
26 February 2008

QRxPharma Initiates Second Phase III Clinical Trial for its ‘Dual Opioid’ Pain Therapy 
13 December 2007

QRxPharma Moving Rapidly with First Patients Enrolled in Phase III Clinical Trial Programme for its “Dual Opioid” Pain Therapy 
The Australian Investor, November 2007

QRxPharma Doses First Patients in Phase III Clinical Trial Program for its ‘Dual Opioid’ Pain Therapy 
26 November 2007

QRxPharma Annual report 2007 
27 September 2007

QRxPharma On Track as Dual Opioid Phase III Trials Approach Full Clinical Readiness 
15 August 2007

JP Morgan Analyst Report 
4 July 2007

QRxPharma Trials Recipe for Pain Relief 
28 June 2007 - The Australian Financial Review

Australian firm combines with local biotech entrepreneur in U.S. venture
21 June 2007 - Washington Business Journal

QRxPharma Completes $50 Million IPO; Trading Commences on the Australian Securities Exchange 
25 May 2007